Companies › Biokin (Shanghai) Biopharmaceutical
2 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BL-M05D1 anti-CLDN18.2 antibody | CLDN18 | Phase 3 | Gastric Cancer; Locally Advanced or Metastatic Solid Tumors | Jun 2027 |
| BL-M14D1 | – | Phase 2 | Extensive-stage Small-cell Lung Cancer; Small Cell Lung Cancer | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06349811 | BL-M05D1 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Jun 2027 |
| NCT06505824 | BL-M14D1 | Phase 1 | Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT07654400 | BL-M14D1 | Phase 2 | Extensive-stage Small-cell Lung Cancer | Oncology | Dec 2027 |
| NCT07518147 | BL-M05D1 | Phase 3 | Gastric Cancer | Oncology | Dec 2029 |
LaNova Medicines Zhejiang Hangzhou Sumgen Biotech Suzhou Immunofoco Biotechnology I-Mab Biopharma US FutureGen Biopharmaceutical (Beijing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.